Advertisement
U.S. markets close in 29 minutes
  • S&P 500

    5,263.89
    +15.40 (+0.29%)
     
  • Dow 30

    39,866.27
    +106.19 (+0.27%)
     
  • Nasdaq

    16,401.93
    +2.41 (+0.01%)
     
  • Russell 2000

    2,124.31
    +9.96 (+0.47%)
     
  • Crude Oil

    83.10
    +1.75 (+2.15%)
     
  • Gold

    2,241.50
    +28.80 (+1.30%)
     
  • Silver

    24.97
    +0.21 (+0.86%)
     
  • EUR/USD

    1.0792
    -0.0037 (-0.35%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2624
    -0.0015 (-0.11%)
     
  • USD/JPY

    151.4090
    +0.1630 (+0.11%)
     
  • Bitcoin USD

    70,708.30
    +1,952.47 (+2.84%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the second quarter will be released after the close of market on Wednesday, August 11, 2021.

About Histogen Inc.

Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including joint cartilage regeneration, spinal disk repair, hair growth and dermal rejuvenation. For more information, please visit www.histogen.com.

CONTACT:

Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com


Advertisement